Assertio Holdings Subsidiary <a href="https://laohu8.com/S/SPPI">Spectrum Pharmaceuticals</a> Amends Supply Agreement with Hanmi Pharmaceutical for Rolvedon Drug Substance
Assertio Holdings Inc. announced that its wholly owned subsidiary, Spectrum Pharmaceuticals, Inc., has entered into an amended and restated supply agreement with Hanmi Pharmaceutical Co. Ltd. for the supply of ROLVEDON drug substance. The amendment establishes long-term pricing following the expiration of fixed pricing provisions in October 2025, reflecting a mid-single digit percentage reduction to the price paid by Spectrum. The new price will remain fixed for the remainder of Spectrum's license agreement with Hanmi, with the potential for price adjustments based on specified cost increases or global market volume thresholds. Spectrum will provide annual forecasted purchase plans, with at least fifty percent of each plan designated as binding. No minimum purchase requirements are included in the agreement, and other supply terms remain materially unchanged.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Assertio Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-098758), on October 10, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.